Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jonathan Wolleben
CJ
Jonathan Wolleben
Citizens JMP
Wall Street Analyst
★★☆☆☆
#2124
on 13Foresight · ranked by our own returns
46%
Success Rate
+1.3%
Average Return
13 of 28 calls profitable · -7.6% vs benchmark
📈 Across the calls we could measure, roughly 46% of Jonathan Wolleben's ratings turned a profit when each position was held for 1 year — averaging +1.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

92 Buy 4 Hold 0 Sell
Jonathan's Stock Coverage 27 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
MIRM
Mirum Pharmaceuticals
 Jun 15, 2026 BUY Strong Buy
+7.0% avg upside
21 analysts
$146.00
36.30% Upside
 +6.1%
SGMT
Sagimet Biosciences, Inc. Class A
 May 19, 2026 BUY Strong Buy
+317.2% avg upside
15 analysts
$12.00
79.64% Upside
 ·
SPRB
Spruce Biosciences
 May 14, 2026 BUY Strong Buy
+90.8% avg upside
14 analysts
$150.00
186.57% Upside
 -16.4%
ALT
Altimmune
 May 14, 2026 BUY Strong Buy
+935.8% avg upside
19 analysts
$11.00
307.43% Upside
 -0.7%
KLRS
Kalaris Therapeutics
 May 13, 2026 BUY Buy
+170.1% avg upside
13 analysts
$25.00
429.70% Upside
 +1.5%
PHVS
Pharvaris
 May 13, 2026 BUY Strong Buy
+37.2% avg upside
14 analysts
$74.00
125.53% Upside
 +1.4%
IRD
Opus Genetics
 May 13, 2026 BUY Strong Buy
+154.5% avg upside
23 analysts
$11.00
170.34% Upside
 -22.2%
MBX
MBX Biosciences, Inc.
 May 12, 2026 BUY Strong Buy
+53.4% avg upside
14 analysts
$86.00
99.92% Upside
 +8.4%
CRNX
Crinetics Pharmaceuticals
 May 08, 2026 BUY Strong Buy
+121.2% avg upside
20 analysts
$95.00
164.78% Upside
 -11.2%
BCRX
BioCryst
 May 07, 2026 BUY Strong Buy
+103.3% avg upside
24 analysts
$28.00
211.46% Upside
 -5.3%
PTGX
Protagonist Therapeutics
 May 06, 2026 BUY Strong Buy
-22.1% avg upside
19 analysts
$137.00
21.40% Upside
 +7.2%
BMEA
Biomea Fusion
 May 05, 2026 BUY Strong Buy
+1037.0% avg upside
15 analysts
$9.00
662.67% Upside
 -4.0%
DBVT
DBV Technologies SA - American
 May 01, 2026 BUY Strong Buy
+55.4% avg upside
15 analysts
$55.00
254.18% Upside
 -18.1%
RYTM
Rhythm Pharmaceuticals
 Mar 17, 2026 BUY Strong Buy
+25.2% avg upside
19 analysts
$152.00
57.06% Upside
 +9.3%
PRQR
ProQR
 Mar 12, 2026 BUY Strong Buy
+516.3% avg upside
18 analysts
$8.00
323.32% Upside
 -15.4%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Feb 27, 2026 BUY Strong Buy
+132.5% avg upside
17 analysts
$113.00
153.94% Upside
 -41.9%
SION
Sionna Therapeutics, Inc.
 Feb 24, 2026 BUY Strong Buy
+45.8% avg upside
11 analysts
$63.00
68.96% Upside
 -0.1%
OCUL
Ocular Therapeutix
 Feb 17, 2026 BUY Strong Buy
+160.4% avg upside
21 analysts
 — +37.9%
QNCX
Quince Therapeutics
 Jan 29, 2026 HOLD Hold
+2750.2% avg upside
13 analysts
 — -60.2%
MDGL
Madrigal Pharmaceuticals
 Jan 20, 2026 BUY Strong Buy
-5.8% avg upside
31 analysts
$745.00
47.36% Upside
 -4.8%
SVRA
Savara
 Oct 23, 2025 BUY Strong Buy
+57.8% avg upside
17 analysts
$11.00
100.08% Upside
 +22.1%
SKYE
Skye Bioscience
 Oct 06, 2025 BUY Strong Buy
+1354.2% avg upside
9 analysts
$4.00
465.55% Upside
 -57.4%
LRMR
Larimar Therapeutics
 Oct 06, 2025 BUY Strong Buy
+409.3% avg upside
21 analysts
$18.00
394.51% Upside
 -29.3%
CLSDQ
Clearside Biomedical
 Jul 17, 2025 HOLD Hold
+10264.6% avg upside
10 analysts
 — -96.8%
AURA
Aura Biosciences Inc
 May 23, 2025 BUY Strong Buy
+233.5% avg upside
9 analysts
$19.00
199.76% Upside
 +29.0%
RLYB
Rallybio
 Apr 23, 2025 HOLD Buy
+14.8% avg upside
8 analysts
 — +258.9%
WMG
Warner Music Group
 May 12, 2023 BUY Strong Buy
+29.9% avg upside
24 analysts
$24.00
14.74% Downside
 +27.9%
🔒 22 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jonathan Wolleben — Frequently Asked Questions
How accurate are Jonathan Wolleben's stock ratings?
Based on the calls 13Foresight could measure, about 46% of Jonathan's ratings were profitable over a one-year hold, with an average return of +1.3% per rating, or -7.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jonathan ranked on 13Foresight?
Jonathan Wolleben is currently ranked #2124 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jonathan cover?
Jonathan most recently has ratings on MIRM, SGMT, SPRB, ALT, KLRS, PHVS, IRD, MBX, CRNX, BCRX, PTGX, BMEA and 15 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.